Adage Capital Partners Gp, L.L.C. Astria Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,601,097 shares of ATXS stock, worth $15.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,601,097Holding current value
$15.2 Million% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
122Shares Held
48.8MCall Options Held
3.59MPut Options Held
483K-
Perceptive Advisors LLC New York, NY6.49MShares$61.4 Million1.91% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.28MShares$50 Million7.82% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$34.2 Million4.36% of portfolio
-
Black Rock Inc. New York, NY3.59MShares$34 Million0.0% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$33.7 Million7.97% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $144M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...